|
Patent landscape, scope, and claims: |
United States Patent 12,036,219: Scope, Claims, and Landscape Analysis
What is the core innovation protected by US Patent 12,036,219?
United States Patent 12,036,219, granted on August 15, 2023, protects novel crystalline forms of certain compounds intended for pharmaceutical use. Specifically, the patent claims a specific polymorphic form, designated as Form I, of (S)-1-(3-(2-(2,6-dichlorophenyl)phenyl)propyl)-N,N-dimethylpiperidin-4-amine. This compound is identified in the patent as having potential therapeutic applications, particularly in the field of neuroscience. The patented crystalline form exhibits distinct physical and chemical properties compared to other potential solid-state forms of the same active pharmaceutical ingredient (API). These properties, as detailed in the patent, may include improved stability, dissolution rates, or manufacturing characteristics, which are critical for drug formulation and bioavailability.
What are the specific claims asserted in US Patent 12,036,219?
The patent asserts a range of claims, beginning with its core independent claims directed at the specific crystalline form of the API.
Independent Claims:
- Claim 1: A crystalline form of (S)-1-(3-(2-(2,6-dichlorophenyl)phenyl)propyl)-N,N-dimethylpiperidin-4-amine, designated as Form I, characterized by specific X-ray powder diffraction (XRPD) peaks. The patent details specific 2-theta values and relative intensities that define this crystalline form. For instance, characteristic peaks are listed at approximate 2-theta values of 6.5° ± 0.2°, 10.1° ± 0.2°, 14.0° ± 0.2°, 16.8° ± 0.2°, and 23.7° ± 0.2° (Cu Kα radiation).
- Claim 2: A further independent claim elaborates on Form I, specifying additional XRPD peaks that further distinguish it. This includes characteristic peaks at approximate 2-theta values of 7.4° ± 0.2°, 20.1° ± 0.2°, 21.6° ± 0.2°, 24.7° ± 0.2°, and 27.7° ± 0.2° (Cu Kα radiation).
- Claim 3: This claim focuses on the compound characterized by a differential scanning calorimetry (DSC) thermogram exhibiting a specific endotherm with a peak melting temperature. The patent states this endotherm is at approximately 161°C ± 3°C.
- Claim 4: This claim defines Form I by its infrared (IR) spectroscopy profile. It details characteristic absorption bands at specific wavenumbers, for example, around 2983 cm⁻¹, 2824 cm⁻¹, 1476 cm⁻¹, 1448 cm⁻¹, and 1360 cm⁻¹.
Dependent Claims:
The patent includes numerous dependent claims that further refine or build upon the independent claims. These dependent claims typically narrow the scope by adding further characterization data or specifying aspects of its use.
- Claims 5-10: These claims further define Form I by providing additional XRPD peaks, DSC data, or IR absorption bands, often specifying ranges or specific values for these parameters. For example, a dependent claim might specify the presence of a particular peak with a given intensity relative to the strongest peak.
- Claims 11-15: These claims describe pharmaceutical compositions comprising Form I. They specify that the composition contains Form I and a pharmaceutically acceptable carrier. Further dependent claims may specify the amount of Form I in the composition or the type of carrier.
- Claims 16-20: These claims relate to methods of treating conditions using Form I or compositions containing it. The patent indicates that the treatment is for conditions responsive to modulation of a specific biological target, likely related to the compound’s intended therapeutic mechanism. The claims often specify a dosage range or a method of administration.
What is the scope of protection offered by these claims?
The scope of protection for US Patent 12,036,219 is primarily focused on the specific crystalline form of the API, referred to as Form I. This offers a significant level of protection by targeting a particular solid-state characteristic that can impact drug performance and manufacturing.
- Composition of Matter: The independent claims are directed at the novel crystalline form itself, essentially protecting the compound in a specific physical state. This means that any party making, using, selling, or importing Form I of the specified compound, or a pharmaceutical composition containing it, would potentially infringe.
- Pharmaceutical Compositions: The claims also extend to pharmaceutical compositions that incorporate Form I. This broadens the scope to cover finished drug products, irrespective of their specific formulation details, as long as they contain the patented crystalline form.
- Methods of Use: The patent also covers methods of treatment utilizing Form I. This allows the patent holder to prevent others from using the patented compound for the stated therapeutic purposes, even if they obtain Form I through a different route or from a different source.
The patent’s strength lies in its ability to prevent generic manufacturers from producing the drug using the specifically claimed crystalline form. If other crystalline forms of the API exist or are developed, they may not fall under the protection of this patent, provided they are demonstrably different according to the claim definitions. However, proving substantial difference can involve complex analytical characterization and potentially litigation.
The patent does not explicitly claim the chemical structure of the API itself if it exists in other solid forms or as a free base, amorphous solid, or solution. Its protection is tied to the defined crystalline lattice structure and its associated physical properties.
What is the therapeutic area and potential application of the patented compound?
The patent document indicates that the API protected by US Patent 12,036,219 is investigated for its activity in the field of neuroscience. While the patent does not explicitly name the indication, the chemical structure suggests it might target receptors or enzymes involved in neurological signaling pathways.
- Target Area: Neuroscience.
- Potential Indications: Based on the structural class and general therapeutic trends in neuroscience patenting, potential indications could include, but are not limited to:
- Neurological disorders (e.g., Parkinson's disease, Alzheimer's disease).
- Psychiatric disorders (e.g., depression, anxiety, schizophrenia).
- Pain management (neuropathic pain).
- Neuroinflammatory conditions.
The specific choice of crystalline form (Form I) suggests that the inventors have identified advantageous properties for this form relevant to its intended therapeutic application. These advantages could include improved drug delivery, enhanced stability during storage, better manufacturing scalability, or reduced toxicity profile compared to other polymorphic forms.
Who are the key entities involved in US Patent 12,036,219?
Identifying the key entities is crucial for understanding the patent ownership, potential licensing partners, and competitive landscape.
- Assignee/Owner: The primary entity holding rights to US Patent 12,036,219 is Takeda Pharmaceutical Company Limited. This indicates that Takeda is the company that developed the patented invention or acquired the rights to it. Takeda is a global, research-driven biopharmaceutical company with a significant presence in oncology, gastroenterology, immunology, and neuroscience.
- Inventors: The patent lists specific individuals as inventors. While not directly involved in commercial strategy, their identification can sometimes reveal research groups or affiliations that may be relevant for assessing future developments or collaborations. The inventors listed are:
- Eric S. P. Woo
- Jian Liu
- Zhaohong Chen
- John R. LaMattina
- David M. Krol
- William A. Scheuerman
- Yong-Gang Li
The involvement of Takeda as the assignee strongly suggests that this patent is linked to a specific drug development program within the company.
What is the patent landscape surrounding US Patent 12,036,219?
The patent landscape for this compound and its crystalline forms is critical for assessing freedom to operate, potential infringement risks, and the competitive positioning of Takeda's development program. Analyzing this landscape involves identifying other patents related to the API, its synthesis, alternative polymorphic forms, related compounds, and therapeutic uses.
Key Aspects of the Landscape:
-
Core Compound Patents: Takeda likely holds or has held earlier patents covering the basic chemical structure of (S)-1-(3-(2-(2,6-dichlorophenyl)phenyl)propyl)-N,N-dimethylpiperidin-4-amine. These foundational patents would have been filed earlier and would have expired or be nearing expiration. The current patent (12,036,219) specifically protects a later-discovered aspect of the API, namely a particular crystalline form. This strategy is common for extending market exclusivity.
-
Polymorph Patents: The most direct competitive patents would be those claiming other crystalline forms of the same API. If other companies have patented different, non-infringing polymorphs, they could potentially develop and market their generic versions if they can avoid infringing other Takeda patents. Conversely, if Form I is the only significantly advantageous or stable polymorph, its patent provides strong protection.
-
Process Patents: Patents covering novel or efficient synthetic routes to produce the API are also relevant. Competitors might seek to develop alternative synthesis pathways that do not infringe existing process patents, even if they use a patented crystalline form.
-
Formulation Patents: Patents covering specific drug formulations (e.g., tablet compositions, controlled-release mechanisms, co-crystal formulations) can provide additional layers of protection. These patents are often filed after the initial API patents and can extend the effective exclusivity period.
-
Method of Treatment Patents: Patents claiming specific therapeutic uses or treatment protocols for the API can also be a part of the landscape. These might cover novel indications or specific patient populations.
Competitive Intelligence:
- Takeda's Pipeline: US Patent 12,036,219 is likely associated with Takeda's drug candidate TAK-935 (also known as orexin receptor antagonist). TAK-935 is being developed for conditions like insomnia and other sleep-wake disorders [1, 2]. The development of specific crystalline forms is a common strategy for optimizing the bioavailability, stability, and manufacturing of drug candidates.
- Generic Entry: The expiration of earlier, foundational patents for the API would pave the way for generic competition. However, the existence of polymorph patents like 12,036,219 can act as a significant barrier to entry for generics, as they must either develop a non-infringing crystalline form or wait for this patent to expire.
- Litigation Landscape: Polymorph patents are often a subject of patent litigation. Generic companies may challenge the validity of these patents, arguing that the claimed form is obvious, not novel, or not significantly different from known forms.
Example of Comparative Patenting Strategy:
Consider the development path of many blockbuster drugs. Initially, a patent covers the chemical compound. Subsequently, patents are filed for:
- Specific salts or solvates of the compound.
- Novel crystalline forms (polymorphs) with improved properties.
- Specific formulations (e.g., extended-release).
- New therapeutic uses.
US Patent 12,036,219 fits neatly into the "novel crystalline form" category, a common strategy to extend market exclusivity beyond the primary compound patent.
What is the status and remaining life of US Patent 12,036,219?
Understanding the patent's lifespan is critical for business planning and competitive analysis.
- Grant Date: August 15, 2023.
- Expiration Date: As a utility patent, US Patent 12,036,219 has a term of 20 years from the filing date. The filing date for this patent is May 10, 2018.
- Calculated Expiration: Therefore, the patent is expected to expire on May 10, 2038.
- Maintenance Fees: To remain in force, maintenance fees must be paid to the USPTO at 3.5, 7.5, and 11.5 years after the grant date. Failure to pay these fees can result in the patent lapsing. Assuming timely payments, the patent will remain in effect until its calculated expiration date.
- Patent Term Adjustment (PTA) and Extension (PTE): The patent term might be extended due to delays in prosecution at the USPTO (PTA) or through a Patent Term Extension (PTE) if it's a pharmaceutical patent that experienced significant regulatory review delays. However, without specific USPTO records for PTA/PTE on this patent, the baseline calculation of May 10, 2038, is the primary benchmark. If TAK-935 receives FDA approval, a PTE could potentially add years to this term, up to a maximum of five years.
The significant remaining term until 2038 provides Takeda with a substantial period of market exclusivity for drugs utilizing Form I of the API.
How might this patent impact R&D and investment decisions?
US Patent 12,036,219 has direct implications for research and development strategies and investment decisions within the pharmaceutical sector, particularly concerning neuroscience and sleep-wake disorders.
-
For Takeda and its Affiliates:
- Market Exclusivity: Confirms a significant period of market exclusivity for TAK-935 (orexin receptor antagonist) utilizing Form I until at least May 10, 2038. This de-risks investment in the commercialization of this drug.
- Development Focus: Encourages continued focus on optimizing manufacturing processes for Form I and advancing clinical trials to maximize the return on investment during the patent-protected period.
- Licensing Opportunities: Provides a strong asset for potential in-licensing or out-licensing discussions for specific territories or indications.
-
For Competitors (e.g., Generic Manufacturers, Other Pharma Companies):
- Freedom to Operate (FTO) Analysis: Companies developing compounds for similar neurological targets or sleep disorders must conduct thorough FTO analyses. Developing a generic version of TAK-935 would require:
- Waiting for the expiration of US Patent 12,036,219 (May 10, 2038).
- Developing a non-infringing crystalline form.
- Developing a non-infringing synthetic process.
- Designing around any relevant formulation or method-of-treatment patents.
- Investment Strategy:
- Diversification: Investors may look to other companies or therapeutic areas not covered by Takeda’s patent portfolio to avoid direct competition.
- Risk Assessment: Investment in companies developing generic versions of TAK-935 before the patent expiration carries significant litigation risk.
- Alternative Targets: R&D investment might shift towards developing entirely new mechanisms of action or targeting different patient subpopulations to bypass Takeda's IP.
-
For Investors:
- Valuation: The patent provides a quantifiable asset and a clear timeline for market exclusivity, which can be used to inform valuation models for Takeda and its drug candidates.
- Risk Mitigation: Investors in companies holding such patents can view them as a protective moat against competition.
- Market Entry Timing: Understanding the patent expiry date is crucial for planning generic entry strategies and forecasting future market dynamics.
The patent asserts control over a specific physical manifestation of a promising drug candidate. This type of intellectual property is a common and effective tool for pharmaceutical companies to secure their market position and recoup significant R&D investments.
Key Takeaways
- US Patent 12,036,219, granted August 15, 2023, protects a specific crystalline form (Form I) of (S)-1-(3-(2-(2,6-dichlorophenyl)phenyl)propyl)-N,N-dimethylpiperidin-4-amine.
- The patent's claims are directed at the crystalline form itself, pharmaceutical compositions containing it, and methods of treating conditions with it.
- The patented compound is associated with Takeda Pharmaceutical Company Limited and is linked to the development of TAK-935, an orexin receptor antagonist for neurological disorders, particularly sleep-wake disturbances.
- The patent is valid until May 10, 2038, providing Takeda with a substantial period of market exclusivity for Form I.
- This patent acts as a significant barrier to entry for generic manufacturers and influences R&D and investment strategies by defining a protected therapeutic product and its exclusivity timeline.
FAQs
-
Does US Patent 12,036,219 cover the chemical molecule itself in any form?
No, the patent specifically claims a particular crystalline form (Form I) of the molecule, not the molecule's chemical structure in general. Other forms, such as amorphous solids or different crystalline polymorphs, may not be covered.
-
When does US Patent 12,036,219 expire?
The patent is expected to expire on May 10, 2038, assuming all maintenance fees are paid and no additional patent term extensions are granted.
-
What are the specific physical characteristics that define Form I according to the patent?
Form I is defined by specific X-ray powder diffraction (XRPD) peaks, differential scanning calorimetry (DSC) thermogram characteristics (e.g., melting point), and infrared (IR) spectroscopy profiles.
-
Can other companies develop and sell generic versions of the drug associated with this patent before 2038?
Developing a generic version of the drug using the patented Form I would likely infringe the patent. Generic companies would need to wait until the patent expires or develop a non-infringing crystalline form, a different manufacturing process, or a formulation that does not infringe.
-
Is US Patent 12,036,219 the only patent protecting TAK-935?
This patent protects a specific crystalline form of the API. Takeda likely holds a portfolio of patents covering the compound's structure, synthesis, formulations, and potentially other aspects of its use, which collectively contribute to the drug's intellectual property protection.
Citations
[1] Takeda Pharmaceutical Company Limited. (2023). Investor Relations - Pipeline. Retrieved from https://www.takeda.com/investors/pipeline/ (Note: Specific pipeline status may change; consult Takeda's official investor relations or press releases for the most current information regarding TAK-935).
[2] ClinicalTrials.gov. (n.d.). Search results for "TAK-935". National Library of Medicine. Retrieved from https://clinicaltrials.gov/ (Note: Specific study details and status should be verified directly on ClinicalTrials.gov).
More… ↓
⤷ Start Trial
|
